ClinicalTrials.gg
Enrolling by invitationNCT05999084Updated Jul 10, 2026

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

An observational study in Alzheimer Disease, sponsored by Emory University. Enrolling by invitation at 8 sites in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Emory University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
735
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Alzheimer Disease by Emory University — 6 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Emory University.

Started
2025
with 1 other
Observational
3 of 28
1 open now
Registered
22nd of 28
by date

Among the 28 studies in Alzheimer Disease by Emory University, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 22nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

6 of the 28 studies in Alzheimer Disease by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Alzheimer Disease by Emory University, or all of them as a file.
02

Study summary

The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.

Read the detailed description

Alzheimer's disease is a devastating neurodegenerative illness impacting millions of Americans including patients and caregivers. Treatments have been limited to symptomatic therapies leading to the pervasive sentiment that 'nothing can be done'; however, recent advances in the field have created excitement and hope for patients, families, and healthcare providers. On 6 January 2023, the anti-amyloid monoclonal antibody (mAb) lecanemab received accelerated approval from the Food and Drug Administration (FDA). A similar medication, donanemab, also recently demonstrated positive results in a large trial. Despite the positive trials, questions remain about anti-amyloid mAbs efficacy as well as how they will perform in a real-world setting. The Centers for Medicare \& Medicaid Services (CMS) released a National Coverage Analysis (NCA) Memo with a framework for deploying anti-amyloid mAbs in a way that improves understanding of benefit and harm.

This registry will be managed through Georgia Memory Net (GMN), an initiative that was launched in 2018 to build statewide capacity for early and specific diagnosis of Alzheimer's disease and related dementias (ADRD), improve patient and caregiver support, and provide access to emerging disease modifying therapies. The GMN supports Memory Assessment Clinics (MACs) geographically distributed at 7 sites around the state with common data elements modeled on best practices developed in the Emory University Cognitive Neurology Memory Assessment Clinic over the past 25 years. The GMN infrastructure and care model provides an optimal real-world testing ground for evidence development on the effectiveness, safety, and appropriate use of anti-amyloid mAbs in the Medicare population.

The clinical data for patients treated with anti-amyloid mAbs will be compared to historical clinical data from comparable patients who were seen in GMN clinics prior to availability of anti-amyloid mAbs. Patients in the registry will be followed for the duration of their initial treatment as specified by FDA for specific anti-amyloid monoclonal antibody and subsequent maintenance treatment which is currently unspecified.

The objectives of this registry are to:

  1. Monitor clinical use of FDA approved anti-amyloid mAbs to report health outcomes for patients in broad community practice.
  2. Understand how patient characteristics, treating clinicians, and clinical settings impact benefits and harms (brain hemorrhage and edema) of FDA approved anti-amyloid mAbs.
  3. Define how benefits and harms of FDA approved anti-amyloid mAbs change over time.
03

Conditions studied

  • Alzheimer Disease

Keywords

  • Monoclonal antibodies
  • Amyloid
  • Mild Cognitive Impairment
  • Lecanemab
  • Leqembi
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study includes patients receiving care through the Emory Cognitive Neurology Clinic and Georgia Memory Net (GMN) clinics, and their caregivers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 50-90, inclusive
  2. Diagnosis: Mild Cognitive Impairment (MCI) or mild AD dementia with positive cerebrospinal fluid (CSF) or amyloid PET
  3. Objective measurement of baseline cognition and function within past 3 months:

    • Cognitive: (MMSE) ≥ 22, MoCA ≥ 16
    • Function: Independence in basic ADLs
    • Function: FAQ ≤ 9 may justify inclusion with lower cognitive score if felt to be impacted by prominent language impairment or other factors affecting score
  4. MRI brain within last year and no exclusionary criteria
  5. Complete blood count (CBC), comprehensive metabolic panel (CMP), B12, thyroid stimulating hormone (TSH), (PT), partial thromboplastin time (PTT), and International Normalized Ratio (INR) without abnormality
  6. Informant/care partner/family available to attend follow-up visits to provide information regarding patient's cognitive and functional abilities
  7. Agree to MRI, PET, and testing clinical diagnostic requirements and drug label / FDA recommendations to determine drug eligibility and appropriateness, including Apolipoprotein E (APOE) testing

Exclusion criteria

Exclusion Criteria:

  1. Any to MRI
  2. MRI exclusion criteria:

    • Acute or sub-acute hemorrhage
    • Prior macro hemorrhage (>1 cm), subarachnoid hemorrhage, or known aneurysm
    • >4 microhemorrhages
    • Superficial siderosis
    • Any finding that might be a contributing cause of the subject's dementia that could pose a risk to the subject or prevent safety MRIs.
  3. Seizure within the past 6 months or history of epilepsy.
  4. Unstable severe psychiatric illness in past 6 months
  5. History of bleeding disorder, blood clotting, or abnormal results on coagulation profile ( count \<50,000; >1.5)
  6. Uncontrolled diabetes (HgbA1c >9%)
  7. Uncontrolled hypertension
  8. History of unstable angina, myocardial infarction (MI), advanced heart failure, or clinically significant conduction abnormalities within past year.
  9. End stage renal disease
  10. Receiving active treatment for cancer (e.g., chemotherapy, biologics, or radiation therapy) with exceptions for maintenance therapies for cancer in remission (e.g., anti-estrogen for breast cancer)
  11. Systemic illness or serious infection, e.g., pneumonia, sepsis, Coronavirus disease 2029 (COVID-19), in past 30 days
  12. Immunological disease requiring , immunoglobulins, monoclonal antibodies, or plasmapheresis
  13. Exclude if breastfeeding or if female patients of unable to practice highly effective
  14. History of severe allergic or anaphylactic reactions or to inactive ingredients (arginine hydrochloride, histidine, histidine hydrochloride monohydrate, polysorbate 80)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
735 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Anti-amyloid Monoclonal Antibodies (mAbs)

    Patients with Mild Cognitive Impairment (MCI) or mild AD dementia who are receiving treatment with anti-amyloid mAbs, per standard of care. Patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.

    Drug: Anti-amyloid Monoclonal Antibodies (mAbs)

  • Historical Comparator Group

    Available historical data from biomarker-confirmed patients with MCI or mild dementia due to AD who have been followed in the Emory Cognitive Neurology Clinic will serve as a comparator group. Patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.

    Combination Product: Standard of Care

  • Caregivers of Patients Receiving Anti-amyloid Monoclonal Antibodies (mAbs)

    Caregivers of patients with Mild Cognitive Impairment (MCI) or mild AD dementia who are receiving treatment with anti-amyloid mAbs, per standard of care. Caregivers of patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.

    Drug: Anti-amyloid Monoclonal Antibodies (mAbs)

Interventions

  • DrugLecanemabStudies of LecanemabLecanemab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.

    Also known as: lecanemab

  • Combination productStandard of Care

    The standard of care, other than treatment with anti-amyloid mAbs, provided at the study clinics.

06

What researchers measure

Primary outcomes

  1. Change in Quick Dementia Rating System (QDRS) Score

    The QDRS is a 10-item questionnaire assessing cognitive impairment. Items are rated on a 5-point scale where no problems = 0, slight problems = 0.5, mild problems = 1, moderate to severe problems = 2, and severe problems = 3. Total scores range from 0 to 30 and higher scores indicate increased cognitive impairment.

    Time frame: Baseline and every 6 months until end of study (up to 5 years)

  2. Montreal Cognitive Assessment (MoCA) Score

    MoCA is an instrument to screen for mild cognitive dysfunction, assessing the cognitive domains of attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Total scores range from 0 to 30 with higher scores indicating better cognitive function. A normal score is considered to be 26 or higher.

    Time frame: Baseline and every 6 months until end of study (up to 5 years)

  3. Change in Functional Activities Questionnaire (FAQ) Score

    Instrumental activities of daily living are assessed with the Functional Activities Questionnaire (FAQ). The FAQ includes 10 items which are scored on a scale from 0 to 3 where 0 = normal and 3 = dependent. Total scores range from 0 to 30 and lower scores indicate that the respondent is able to perform daily activities. A score of 9 (where the person is dependent in 3 activities) is used as a cut-point indicating impairments with functioning.

    Time frame: Baseline and every 6 months until end of study (up to 5 years)

  4. Change in Lawton-Brody Activities of Daily Living (ADL) Physical Self-Maintenance Scale (PSMS) Score

    Independence with tasks such as toilet behaviors, feeding, and grooming is measured with the Physical Self-Maintenance Scale (PSMS). The PSMS is a 6-item instrument with multiple options for responses, which are scored as 0 or 1. Complete independence with the activity is scored as 1 and if any sort of assistance is needed the score is 0 . Total scores range from 0 to 6 with higher scores indicating greater independence with tasks of self-maintenance.

    Time frame: Baseline and every 6 months until end of study (up to 5 years)

  5. Change in Lawton-Brody Instrumental Activities of Daily Living (IADL) Scale Score

    Functional independence is measured with the Instrumental Activities of Daily Living (IADL) scale. The IADL is an 8-item instrument which assesses how well the respondent can perform daily tasks of using the telephone, shopping, food preparation, housekeeping, laundry, transport, medication, and finances by rating the responses as 0 or 1. The total score for women ranges from 0 to 8 and the total score for men ranges from 0 to 5, with higher scores indicating greater independence.

    Time frame: Baseline and every 6 months until end of study (up to 5 years)

Secondary outcomes

  1. Change in Care Needs Assessment Tool (CNAT) Score

    The CNAT asks caregivers to indicate whether or not certain challenging behaviors (9 items) or difficulties with activities of daily living (4 items) have occurred with the care recipient in the past month. For the behaviors and difficulties that have happened, caregivers rate how much they were bothered by this on a 5-point scale where "not at all" = 0 and "extremely" = 4. Total score for this section range from 0 to 52, with higher scores indicating a increased feelings of being upset about the behaviors and functional difficulties of the care recipient.

    Time frame: Baseline and every 6 months until end of study (up to 5 years)

  2. Change in Zarit Burden Interview Score

    The Zarit Burden Interview instrument assesses caregiver burden and needs. The measurement has 22 items about feelings while caring for another person and each item on the interview is a statement which the caregiver is asked how often they feel that way. Responses are given on a 5-point scale where Never - 0 and Nearly Always = 4. Total scores range from 0 to 88 and higher scores indicate greater feelings of burden.

    Time frame: Baseline and every 6 months until end of study (up to 5 years)

  3. Change in Patient-Reported Outcomes Measurement Information System Global Health (PROMIS 10) Score

    The PROMIS Global Health questionnaire consists of 10 items assessing general domains of health and functioning. Items are scored on a 5-point scale where poor = 1 and excellent = 5. Total scores are standardized to a T-score with a mean of 50 and a standard deviation of 10. Scores above 50 indicate better health and functioning, while scores below 50 indicate physical, mental and social health that is below average.

    Time frame: Baseline and every 6 months until end of study (up to 5 years)

07

Study locations

8 sites
  • Georgia Memory Net Memory Assessment Clinic - Albany
    Albany, Georgia 31707, United States
  • Georgia Memory Net Memory Assessment Clinic - Atlanta
    Atlanta, Georgia 30303, United States
  • Emory Cognitive Neurology Clinic at the Emory Brain Health Center
    Atlanta, Georgia 30322, United States
  • Georgia Memory Net Memory Assessment Clinic - Augusta
    Augusta, Georgia 30912, United States
  • Georgia Memory Net Memory Assessment Clinic - Gainesville
    Gainesville, Georgia 30501, United States
  • Georgia Memory Net Memory Assessment Clinic - Macon
    Macon, Georgia 31206, United States
  • Georgia Memory Net Memory Assessment Clinic - Savannah
    Savannah, Georgia 31406, United States
  • Georgia Memory Net Memory Assessment Clinic - Vidalia
    Vidalia, Georgia 30474, United States
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data regarding the results of longitudinal cognitive testing and functional surveys, and type, frequency, and severity of adverse events, will be available for sharing with other researchers.

Supporting information: Study protocol

Time frame: Data will be made publicly available upon completion of this study and initial publication of findings from this study. Earlier access may be provided to the Centers for Medicare \& Medicaid Services (CMS) or other groups who demonstrate a legitimate need for access to data.

Access criteria: Data may be made available on request and at the discretion of the PI to CMS, other federal agencies, academic organizations, and other legitimate researchers. Data will be available for sharing for the purposes of outcome studies to evaluate the benefits and risks associated with use of lecanemab. Requests can be submitted to Georgia Memory Net (GMN) and the PI. Data request form will be made accessible on the GMN web site.

Data sharing details ↗ · gamemorynet.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jul 2028, 40 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 40 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2023
First posted
Aug 21, 2023
StartActual
Mar 6, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05999084
Lead sponsor
Emory University
Collaborators
Centers for Medicare and Medicaid Services
Responsible party
James Lah (Associate Professor, Emory University) — Principal investigator
First posted
Aug 21, 2023
Start date
Mar 6, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

James J Lah, MD, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion